← Back to Calendar

Cytokinetics Q4 2025 Earnings

Cytokinetics · $CYTK

Standard Review Earnings

PDUFA Date

February 27, 2026

Time Remaining

25d ago

Review Type

Standard (10 mo)

Indication

Q4 2025 earnings + MYQORZO commercial launch update

Key Notes

Q4 2025 earnings reported February 27, 2026. Q4 revenue $17.8M (FY2025 $88.0M including $52.4M Bayer tech transfer). Net loss Q4 $183M (-$1.50/sh). Year-end cash ~$1.22B. MYQORZO FDA approved Dec 19 2025; launched Jan 2026. Key updates: ACACIA-HCM (non-obstructive) readout expected Q2 2026; MAPLE-HCM sNDA review expected by Q4 2026.

⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

← Back to Full Calendar